Brainomix Secures £14M Funding to Expand Innovative AI Solutions
Brainomix Raises £14M to Propel AI Innovation in Healthcare
Brainomix, a pioneering healthcare company focused on AI-powered imaging tools, has successfully completed a £14 million ($18 million) Series C funding round. This significant investment is co-led by distinguished healthtech investors, including Parkwalk Advisors and the Boehringer Ingelheim Venture Fund, along with the new investor, Hostplus. This funding is set to bolster their innovative solutions aimed at improving the diagnosis and treatment of stroke and lung fibrosis.
Commercial Expansion and New Developments
As a spinout from the University of Oxford, Brainomix has made impressive strides in commercializing its technology, servicing more than 20 countries globally. Their flagship product, Brainomix 360 Stroke, streamlines the use of validated imaging biomarkers to enhance treatment decisions for stroke patients. Impressively, this advanced AI platform has been adopted in over 300 hospitals, benefiting more than 1.5 million patients.
The Impact of Brainomix 360 Stroke
Brainomix 360 Stroke has demonstrated a remarkable impact on treatment rates. Research indicates that its implementation is associated with a 50% increase in patients receiving mechanical thrombectomy, a critical procedure that substantially reduces disability after stroke.
Future Plans and US Expansion
This latest funding round will enable Brainomix to accelerate its expansion into the US market, where the company has recently received ten FDA clearances. The fresh capital will also help develop additional AI-driven technologies focusing on faster diagnoses and expanding access to essential treatments for various conditions.
Technology for Lung Fibrosis and Strategic Partnerships
In addition to stroke technology, Brainomix has expanded its focus to lung fibrosis. The development of their Brainomix 360 e-Lung is pioneering in predicting disease progression accurately. The company has partnered with Boehringer Ingelheim to assess the impact of this technology on enhancing treatment access for those suffering from lung fibrosis.
Leadership Insights
Dr. Michalis Papadakis, CEO and Co-Founder at Brainomix, expressed gratitude to the investors for their support, emphasizing the transformative potential of their technology for stroke and lung fibrosis patients. Meanwhile, John Pearson, Chief Investment Officer at Parkwalk, highlighted the significant societal impact and growth generated by Brainomix's AI platforms in healthcare.
Commitment to Transformative Healthcare Solutions
Dr. Oliver Reuss, Investment Manager of the Boehringer Ingelheim Venture Fund, commended Brainomix on its history of delivering effective AI solutions for clinical practice, stating their ongoing efforts to relieve lung disease burdens.
About Brainomix
Brainomix is dedicated to creating AI-imaging software that enhances precision medicine and improves treatment decisions in both stroke and lung fibrosis. With its emergence from the University of Oxford, the company is rapidly expanding its presence across the UK, Ireland, and the USA, reaching over 20 countries. As a private enterprise supported by leading healthtech investors, Brainomix has made notable advancements in imaging biomarkers and software solutions actively utilized in numerous hospitals worldwide. Their first product, Brainomix 360 Stroke, remains a leading choice among clinicians for its comprehensive imaging capabilities that facilitate better patient outcomes.
Frequently Asked Questions
What is the purpose of Brainomix's recent funding round?
The funding is aimed at expanding their AI imaging technology for stroke and lung fibrosis, particularly focusing on commercial expansion in the US.
How does Brainomix's technology improve patient outcomes?
Brainomix 360 Stroke has been linked to a significant increase in patients receiving mechanical thrombectomy, enhancing their recovery and reducing disability.
Which new markets is Brainomix looking to enter?
Brainomix aims to expand its presence in the US market, having already secured multiple FDA clearances for its technologies.
What is Brainomix 360 e-Lung?
Brainomix 360 e-Lung is an AI-driven tool designed to predict the progression of lung fibrosis, enhancing treatment identification for patients.
Who are Brainomix's main investors?
Key investors include Parkwalk Advisors, Boehringer Ingelheim Venture Fund, and the new investor Hostplus.
About The Author
Contact Thomas Cooper privately here. Or send an email with ATTN: Thomas Cooper as the subject to contact@investorshangout.com.
About Investors Hangout
Investors Hangout is a leading online stock forum for financial discussion and learning, offering a wide range of free tools and resources. It draws in traders of all levels, who exchange market knowledge, investigate trading tactics, and keep an eye on industry developments in real time. Featuring financial articles, stock message boards, quotes, charts, company profiles, and live news updates. Through cooperative learning and a wealth of informational resources, it helps users from novices creating their first portfolios to experts honing their techniques. Join Investors Hangout today: https://investorshangout.com/
The content of this article is based on factual, publicly available information and does not represent legal, financial, or investment advice. Investors Hangout does not offer financial advice, and the author is not a licensed financial advisor. Consult a qualified advisor before making any financial or investment decisions based on this article. This article should not be considered advice to purchase, sell, or hold any securities or other investments. If any of the material provided here is inaccurate, please contact us for corrections.
